Emmanuel Papadakis

Stock Analyst at Deutsche Bank

(0.86)

# 2,781

Out of 4,479 analysts

28

Total ratings

46.67%

Success rate

-3.99%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Biotechnology Drug Manufacturers - Specialty & Generic

11 Stocks

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	GRFS Grifols	Downgrades: Sell	n/a	$6.52	-	2	Mar 12, 2024
	AZN AstraZeneca	Downgrades: Hold	n/a	$76.99	-	2	Feb 8, 2024
	MRNA Moderna	Downgrades: Sell	n/a	$117.07	-	6	Nov 2, 2023
	BNTX BioNTech SE	Maintains: Hold	$135 → $120	$78.76	+52.36%	6	May 18, 2023
	ALVO Alvotech	Maintains: Hold	$8 → $12	$12.24	-1.96%	2	Mar 7, 2023
	SNY Sanofi	Upgrades: Hold	n/a	$48.54	-	2	Aug 12, 2022
	NVO Novo Nordisk	Upgrades: Buy	n/a	$142.98	-	2	Mar 16, 2022
	NVS Novartis AG	Downgrades: Sell	n/a	$106.44	-	2	Sep 20, 2021
	ARGX argenx SE	Initiates: Hold	n/a	$435.49	-	1	Jul 23, 2021
	RHHBY Roche Holding AG	Upgrades: Buy	n/a	$34.41	-	1	Jul 8, 2021
	GSK GSK	Downgrades: Sell	n/a	$38.21	-	2	Feb 4, 2021

Grifols

Mar 12, 2024

Downgrades: Sell

Price Target: n/a

Current: $6.52

Upside: -

AstraZeneca

Feb 8, 2024

Downgrades: Hold

Price Target: n/a

Current: $76.99

Upside: -

Moderna

Nov 2, 2023

Downgrades: Sell

Price Target: n/a

Current: $117.07

Upside: -

BioNTech SE

May 18, 2023

Maintains: Hold

Price Target: $135 → $120

Current: $78.76

Upside: +52.36%

Alvotech

Mar 7, 2023

Maintains: Hold

Price Target: $8 → $12

Current: $12.24

Upside: -1.96%

Sanofi

Aug 12, 2022

Upgrades: Hold

Price Target: n/a

Current: $48.54

Upside: -

Novo Nordisk

Mar 16, 2022

Upgrades: Buy

Price Target: n/a

Current: $142.98

Upside: -

Novartis AG

Sep 20, 2021

Downgrades: Sell

Price Target: n/a

Current: $106.44

Upside: -

argenx SE

Jul 23, 2021

Initiates: Hold

Price Target: n/a

Current: $435.49

Upside: -

Roche Holding AG

Jul 8, 2021

Upgrades: Buy

Price Target: n/a

Current: $34.41

Upside: -

GSK

Feb 4, 2021

Downgrades: Sell

Price Target: n/a

Current: $38.21

Upside: -